{"id":990599,"date":"2026-08-05T20:17:04","date_gmt":"2026-08-06T00:17:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/orasure-announces-second-quarter-2026-financial-results\/"},"modified":"2026-08-05T20:17:04","modified_gmt":"2026-08-06T00:17:04","slug":"orasure-announces-second-quarter-2026-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/orasure-announces-second-quarter-2026-financial-results\/","title":{"rendered":"OraSure Announces Second Quarter 2026 Financial Results"},"content":{"rendered":"
\n

BETHLEHEM, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) — OraSure Technologies, Inc. (Nasdaq: OSUR), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced its financial results for the three months ended June 30, 2026.<\/p>\n

\u201cOur Q2 results demonstrate continued progress in our return-to-growth trajectory, with revenue of $30.6 million, up 9.7% sequentially and above our guidance range, along with solid gross margin improvement,\u201d said Carrie Eglinton Manner, President and CEO of OTI. \u201cWe also advanced key innovation milestones, including recent FDA clearance of our Colli-Pee\u2122\u2022Dx at-home urine collection device for sexually transmitted infections, and FDA Emergency Use Authorization of our OraQuick\u2122 Ebola 2.0 Rapid Antigen Test.\u201d<\/p>\n

\u201cThese achievements reflect our strategy to decentralize diagnostics and connect people to care that is more accessible, convenient, affordable, and private,\u201d she continued. \u201cSupported by a strong balance sheet, we have the flexibility and capacity to pursue targeted growth initiatives by investing in innovation and bringing it to scale while maintaining the potential to strengthen our portfolio through strategic collaborations and acquisitions.”<\/p>\n

\n Financial Highlights ($ in 000\u2019s, except per share amounts)<\/strong>\n <\/p>\n\n\n\n\n\n\n\n
\u00a0<\/td>\n\n For the Three Months Ended June 30,<\/strong>\n <\/td>\n\u00a0<\/td>\n\n For the Six Months Ended
June 30,<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\n 2026<\/strong>
\n \n <\/td>\n		\u00a0<\/td>\n\n 2025<\/strong>
\n \n <\/td>\n		\u00a0<\/td>\n\n % Change<\/strong>\n <\/td>\n\u00a0<\/td>\n\n 2026<\/strong>
\n \n <\/td>\n		\u00a0<\/td>\n\n 2025<\/strong>
\n \n <\/td>\n		\u00a0<\/td>\n\n % Change<\/strong>\n <\/td>\n<\/tr>\n
Core Business(1)<\/sup><\/td>\n$<\/td>\n30,638<\/td>\n\u00a0<\/td>\n$<\/td>\n30,768<\/td>\n\u00a0<\/td>\n\u2014<\/td>\n%<\/td>\n\u00a0<\/td>\n$<\/td>\n58,545<\/td>\n\u00a0<\/td>\n$<\/td>\n58,822<\/td>\n\u00a0<\/td>\n\u2014<\/td>\n%<\/td>\n<\/tr>\n
COVID-19<\/td>\n\u00a0<\/td>\n1<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n28<\/td>\n\u00a0<\/td>\n(96<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n19<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n485<\/td>\n\u00a0<\/td>\n(96<\/td>\n)%<\/td>\n<\/tr>\n
Risk Assessment Testing<\/td>\n\u00a0<\/td>\n\u2014<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n446<\/td>\n\u00a0<\/td>\n(100<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u2014<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n1,866<\/td>\n\u00a0<\/td>\n(100<\/td>\n)%<\/td>\n<\/tr>\n
\n Total Net Revenues<\/strong>\n <\/td>\n$<\/td>\n30,639<\/td>\n\u00a0<\/td>\n$<\/td>\n31,242<\/td>\n\u00a0<\/td>\n(2<\/td>\n)%<\/td>\n\u00a0<\/td>\n$<\/td>\n58,564<\/td>\n\u00a0<\/td>\n$<\/td>\n61,173<\/td>\n\u00a0<\/td>\n(4<\/td>\n)%<\/td>\n<\/tr>\n<\/table>\n

\n (1)<\/sup> Includes Diagnostics, Sample Management Solutions, other products and services revenues, and non-product and services revenues.<\/p>\n

\n \n <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\u00a0<\/td>\n\n For the Three Months Ended
June 30,<\/strong>\n <\/td>\n		\u00a0<\/td>\n\n For the Six Months Ended
June 30,<\/strong>\n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\n 2026<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n 2025<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n % Change<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n 2026<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n 2025<\/strong>\n <\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n % Change<\/strong>\n <\/td>\n<\/tr>\n
Net revenues<\/td>\n\u00a0<\/td>\n30,639<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n31,242<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(2)%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n58,564<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n61,173<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(4)%<\/td>\n<\/tr>\n
Gross profit<\/td>\n\u00a0<\/td>\n13,317<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n13,159<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n1<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n25,121<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n25,458<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(1)<\/td>\n<\/tr>\n
Gross margin<\/td>\n\u00a0<\/td>\n43.5<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n42.1<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n42.9<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n41.6<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Non-GAAP gross profit<\/td>\n\u00a0<\/td>\n13,556<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n13,512<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u2014<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n25,663<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n25,980<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(1)<\/td>\n<\/tr>\n
Non-GAAP gross margin<\/td>\n\u00a0<\/td>\n44.2<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n43.2<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n43.8<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n42.5<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Operating income (loss)<\/td>\n\u00a0<\/td>\n5,440<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(18,026<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(17,829<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(35,776<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n<\/tr>\n
Operating margin<\/td>\n\u00a0<\/td>\n17.8<\/td>\n%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(57.7<\/td>\n)%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(30.4<\/td>\n)%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(58.5<\/td>\n)%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Non-GAAP operating loss<\/td>\n\u00a0<\/td>\n(14,740<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(13,172<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(33,774<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(28,452<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n<\/tr>\n
Non-GAAP operating margin<\/td>\n\u00a0<\/td>\n(48.1<\/td>\n)%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(42.2<\/td>\n)%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(57.7<\/td>\n)%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(46.5<\/td>\n)%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Net income (loss)<\/td>\n\u00a0<\/td>\n6,249<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(19,693<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(16,128<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(35,733<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n<\/tr>\n
Non-GAAP net loss<\/td>\n\u00a0<\/td>\n(13,817<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(14,193<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(30,839<\/td>\n)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n(27,332<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n<\/tr>\n
Diluted EPS<\/td>\n$<\/td>\n0.09<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$<\/td>\n(0.26<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n$<\/td>\n(0.23<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(0.48<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n<\/tr>\n
Non-GAAP Diluted EPS<\/td>\n$<\/td>\n(0.20<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(0.19<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n\u00a0<\/td>\n$<\/td>\n(0.44<\/td>\n)<\/td>\n\u00a0<\/td>\n$<\/td>\n(0.37<\/td>\n)<\/td>\n\u00a0<\/td>\nNM<\/td>\n<\/tr>\n<\/table>\n

NM \u2013 not meaningful<\/p>\n

\n \n <\/p>\n

For additional information on non-GAAP financial measures and a reconciliation of the GAAP financial results to non-GAAP financial results, see the schedules below. A description of the adjustments made to the GAAP financial measures is included at the end of the schedules.<\/p>\n